Intangible Assets

MEDS does not show evidence of durable brand, patent, or regulatory exclusivity in the provided metrics, so it lacks the kind of intangible protection that would sustain pricing power versus peers.

The absence of 5-year margin and return history in the supplied data makes it difficult to infer any persistent proprietary advantage, while peers with protected formulations or stronger brands would typically show more stable economics.

A negative TTM ROIC of -4.4% suggests any intangible edge is not currently translating into superior after-tax returns, which is weak relative to peers with proven monetizable IP.

Switching Costs

The provided metrics do not indicate customer lock-in, workflow integration, or contractual stickiness, so retention appears more dependent on price and availability than on switching friction.

Negative ROIC and low asset turnover are inconsistent with a business where customers are highly embedded, because strong switching costs usually support steadier margins and capital efficiency than peers.

Compared with healthcare peers that benefit from formulary, prescribing, or platform integration effects, MEDS shows no clear evidence of comparable retention power.

Network Effects

The supplied data contains no sign of user-to-user, data, or ecosystem feedback loops that would make the business more valuable as scale increases.

A negative ROIC and limited efficiency evidence do not support a self-reinforcing platform dynamic, which is typically visible in peers with network-driven advantages.

Relative to peer businesses with distribution or data networks, MEDS appears to operate without a material network effect moat.

Cost Advantage

The TTM asset turnover of 0.245 is low, which suggests weak asset productivity rather than a clear cost advantage versus peers.

Negative ROIC indicates the company is not currently converting its cost structure into superior economic returns, which argues against a durable unit-cost edge.

Any scale-related purchasing or operating leverage is not evident in the supplied metrics, so peers with better utilization likely have stronger cost positions.

Efficient Scale

The available data does not show evidence that MEDS serves a niche where limited market size protects returns from competition, which is the core requirement for efficient scale.

Low asset turnover and negative ROIC imply the business is not extracting strong economics from its asset base, unlike peers that can profitably dominate a constrained niche.

There is no indication of industry structure or capacity discipline in the provided metrics that would allow MEDS to sustain above-peer margins through efficient scale.

Overall Score

MEDS appears to have a weak moat versus peers because the supplied metrics show no durable evidence of intangible protection, switching costs, network effects, cost advantage, or efficient scale, and the negative TTM ROIC suggests limited pricing power or retention strength.